Skip to content

Intraoperative Infusion of Methylene Blue for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac Surgery.

Intraoperative Infusion of Methylene Blue for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac and nonneurosurgical Surgery.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020596
Enrollment
Unknown
Registered
2019-01-09
Start date
2019-01-14
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Delirium and Postoperative Cognitive Dysfunction

Interventions

Group 1:2mg/kg methylene blue diluted with normal saline into total 50 ml volume
Group 2:0.9% normal saline 50ml

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Men and women patients aged 60-80 years who plan to undergo non-cardiac and non-neurosurgical surgery under general anesthesia; 2. No methylene blue taboo; 3. All patients were screened with a Mini-Mental State Examination (MMSE), and those with scores are greater than or equal to 20; 4. The liver and kidney function are normal; 5. All patients have the ability to act in full spirit, understand and sign the informed consent, and are willing to complete the whole research process.

Exclusion criteria

Exclusion criteria: 1. The patient is allergic to methylene blue and its injection components; 2. The patient has 6-phospho-glucose dehydrogenase deficiency (vicia faba disease); 3. Recent history of administration of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors; 4. History of major head trauma; 5. The patient has a history of drug or alcohol abuse; 6. The patient has serious mental or neurological disorders; 7. Patients with severe language, hearing and visual impairment cannot communicate; 8. Patients have serious medical diseases, such as heart failure, acute stage of myocardial infarction or respiratory failure; 9. In the last 3 months, they have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
postoperative delirium;

Secondary

MeasureTime frame
Superoxide Dismutase;Homocysteine;postoperative cognitive dysfunction;

Countries

China

Contacts

Public ContactZhang Jun

Huashan Hospital, Fudan University

snapzhang@aliyun.com+86 13817153025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026